Apellis Pharmaceuticals (APLS) PT Lowered to $48 at Stifel - Aims to Grow in 2026
Tweet Send to a Friend
Stifel analyst Annabel Samimy lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $48.00 (from $55.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
